Wire Stories

SkyDrive Selected for Innovation Grant Worth up to 12.4 Billion Yen by Japanese Government

TOYOTA, Japan--(BUSINESS WIRE)--#FlyingCars--SkyDrive Inc. (“SkyDrive”), a leading Japanese eVTOL aircraft (*1) manufacturer based in Japan, is pleased to announce that…

2 years ago

Fearless, Solid and Reliable, DONGFENG KC Ushers a New Journey in the World

WUHAN, China--(BUSINESS WIRE)--Customer-oriented, in response to the dominance of road transport in many regions around the world, Dongfeng Commercial Vehicles…

2 years ago

HighField Biopharmaceuticals Announces Positive Phase 1a Data of HF1K16, a new Immuno-Oncology Drug, For Patients with Recurrent and Refractory Glioma

HighField CEO Yuhong Xu and CBO Donald Wyatt are attending BIO-Europe, November 6 – 8, 2023 to discuss these significant…

2 years ago

Genexine and KGbio received the first market approval for novel long-acting Erythropoietin, Efepoetin alfa, from The Indonesian Food and Drug Authority (BPOM)

First market approval for Genexine discovered and developed therapeutic drug, Efesa (Efepoetin alfa), a long-acting erythropoietin (EPO) for the treatment…

2 years ago

National Football League Teams Up with SES for Game Content Distribution

In a renewed partnership, SES’s hybrid distribution network to enable the NFL to reach over 35 partners in Europe, Asia…

2 years ago

Celltrion, Inc. & Celltrion Healthcare Co., Ltd. Announce Shareholders Approval of Merger

On October 23rd, at the EGM of shareholders, the merger agreement between Celltrion, Inc. & Celltrion Healthcare Co., Ltd. was…

2 years ago

Nidec Announces Financial Results for Fiscal Second Quarter and Six Months Ended September 30, 2023

KYOTO, Japan--(BUSINESS WIRE)--Nidec Corporation (TOKYO:6594) (OTC US:NJDCY) today announced its consolidated financial results under the International Financial Reporting Standards (“IFRS”)…

2 years ago

Nidec Announces Differences between Projected and Actual Financial Results for First-Half FY2023

KYOTO, Japan--(BUSINESS WIRE)--Nidec Corporation (TOKYO: 6594; OTC US: NJDCY) (the “Company”) today announced differences between its financial forecast for the…

2 years ago

ENHERTU® Approved in the EU as the First HER2 Directed Therapy for Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer

Approval based on DESTINY-Lung02 trial results where Daiichi Sankyo and AstraZeneca’s ENHERTU demonstrated a confirmed objective response rate of 49.0%…

2 years ago

Bias in AI Computer Vision Systems Dramatically Reduced with Synthetic Data ‘Digital Humans’

Mindtech’s Digital DNA technology creates a diverse range of Digital Humans that allow for statistically fair representation of the eight…

2 years ago